Polymer MRI Contrast Agent With Sub-20 Nm Single-Chain Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MRI contrast agents struggle to effectively differentiate tumors of various organs due to rapid diffusion and excretion, limiting their imaging effectiveness, and existing nanoparticle-based drug delivery systems face challenges in precisely controlling particle diameter below 20 nm to enhance tumor accumulation and diagnostic accuracy.
Innovation Solution
A terpolymer-based polymer contrast agent is developed, capable of forming single-chain nanoparticles (SCNPs) with controlled particle diameters of 20 nm or less, incorporating paramagnetic metal complexes to enhance MRI imaging of malignant tumors by selectively accumulating in tumor tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional contrast agents are used, then imaging can be performed, but the contrast agent diffuses rapidly and is excreted quickly, limiting imaging time and effectiveness
Solution Approach 1:
The patent uses a composite structure consisting of a polymer backbone with pendant chelating groups that coordinate paramagnetic metal ions (Gd³⁺, Mn²⁺). This composite design creates a macromolecular contrast agent where multiple chelating units are spaced apart to prevent aggregation while maintaining high metal ion loading, thereby extending circulation time and reducing renal clearance compared to small molecular contrast agents
2Measurement precision
If nanoparticle size is reduced below 20 nm to enhance tumor accumulation via EPR effect, then diagnostic accuracy improves, but precise control of particle diameter becomes difficult
Solution Approach 1:
The patent employs systematic variation of polymerization parameters including monomer ratio, chain transfer agent concentration, and reaction temperature to precisely control the molecular weight and hydrodynamic diameter of the synthesized nanoparticles. By adjusting the ratio of hydrophilic to hydrophobic monomers and controlling chain transfer reactions, the patent achieves consistent particle sizes in the 10-20 nm range optimal for EPR effect-mediated tumor accumulation
3Measurement precision
If contrast agent concentration is increased to improve imaging ability, then diagnostic accuracy enhances, but side effects increase
Solution Approach 1:
The patent creates nanoparticles with heterogeneous structure where hydrophobic core regions concentrate paramagnetic metal ions for high contrast enhancement, while hydrophilic surface regions provide biocompatibility and reduce toxicity. This spatial separation of functions allows the contrast agent to achieve high imaging effectiveness at low systemic concentrations, minimizing side effects while maintaining excellent tumor detection capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer contrast agent exhibits improved imaging ability and temporal contrast in tumor-bearing mice, providing enhanced diagnostic accuracy with reduced side effects at low doses.
Implementation Method 1
a copolymer (hereinafter, also referred to as a chelating agent-bonded copolymer) in which a chelating agent molecule is bonded to a copolymer X having structural units represented by formulas (A), (B), and (C)... the copolymer spontaneously associates in an aqueous medium to form core-shell type nanoparticles (polymeric micelles)
Implementation Method 2
a paramagnetic metal-containing polymer contrast agent... Gadolinium (Gd), which is a paramagnetic material, is often used as the contrast agent in the contrast MRI
Data Source
AI summary
A copolymer includes a copolymer X and a chelating agent molecule bonded to the copolymer X. The copolymer X includes structural units of (A), (B), and (C),where R1, R2, and R3 are independently a hydrogen or a C1-3 alkyl, R4 is a C1-3 alkyl, R5 is a hydrogen, a C1-18 alkyl, a 3- to 8-membered cycloalkyl optionally having a substituent, an adamantyl, a C6-18 aryl optionally having a substituent, or a 5- to 10-membered heteroaryl group optionally having a substituent, X1, X2, and X3 are independently an oxygen, a sulfur, or N—R7, R6 is a hydrogen, a leaving group, or a linker, R7 is a hydrogen or a C1-3 alkyl group, m is an integer in the range of 1 to 100, and n is an integer in the range of 0 to 3.